EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PARP Inhibitors in Breast and Ovarian Cancer

Samuel S Y Wang iD, Yeo Ee Jie, Sim Wey Cheng, Goh Liuh Ling, Heong Valerie Yue Ming iD

Cancers · 18.04.2023 · 15 (8) · 2357

DOI: 10.3390/cancers15082357 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 18.04.2023. Verfasst von Samuel S Y Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Tan Tock Seng Hospital, Singapore 308433, Singapore. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSCS-LKC-NHG, National Health Group-Lee Kong Chian, NHG-LKCMedicine Clinician-Scientist Career Scheme (CSCS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poly (ADP-ribose) polymerase (PARP) inhibitors are one of the most successful examples of clinical translation of targeted therapies in medical oncology, and this has been demonstrated by their effective management of BRCA1/BRCA2 mutant cancers, most notably in breast and ovarian cancers. PARP inhibitors target DNA repair pathways that BRCA1/2-mutant tumours are dependent upon. Inhibition of the key components of these pathways leads to DNA damage triggering subsequent critical levels of genomic instability, mitotic catastrophe and cell death. This ultimately results in a synthetic lethal relationship between BRCA1/2 and PARP, which underpins the effectiveness of PARP inhibitors. Despite the early and dramatic response seen with PARP inhibitors, patients receiving them often develop treatment resistance. To date, data from both clinical and preclinical studies have highlighted multiple resistance mechanisms to PARP inhibitors, and only by understanding these mechanisms are we able to overcome the challenges. The focus of this review is to summarise the underlying mechanisms underpinning treatment resistance to PARP inhibitors and to aid both clinicians and scientists to develop better clinically applicable assays to better select patients who would derive the greatest benefit as well as develop new novel/combination treatment strategies to overcome these mechanisms of resistance. With a better understanding of PARP inhibitor resistance mechanisms, we would not only be able to identify a subset of patients who are unlikely to benefit from therapy but also to sequence our treatment paradigm to avoid and overcome these resistance mechanisms.

Schlagwörter

Stichwörter der Autor:innen

BRACA2BRCA1PARP inhibitorbreast cancerovarian cancer

Autor:innen und Institutionen

  • Medical Oncology, Tan Tock Seng Hospital, Singapore 308433, Singapore.
  • Molecular Diagnostic Laboratory, Tan Tock Seng Hospital, Singapore 308433, Singapore.

ORCID-Profile: Samuel S Y Wang, Heong Valerie Yue Ming

Förderung

  • CSCS-LKC-NHG
  • National Health Group-Lee Kong Chian, NHG-LKCMedicine Clinician-Scientist Career Scheme (CSCS)

Zitieren

APA

Wang, S. S. Y., Jie, Y. E., Cheng, S. W., Ling, G. L., & Ming, H. V. Y. (2023). PARP Inhibitors in Breast and Ovarian Cancer. Cancers, 15(8), 2357. https://doi.org/10.3390/cancers15082357

Vancouver

Wang SSY, Jie YE, Cheng SW, Ling GL, Ming HVY. PARP Inhibitors in Breast and Ovarian Cancer. Cancers. 2023;15(8):2357. doi:10.3390/cancers15082357

BibTeX
@article{Wang2023,
  author = {Wang, Samuel S Y and Jie, Yeo Ee and Cheng, Sim Wey and Ling, Goh Liuh and Ming, Heong Valerie Yue},
  title = {PARP Inhibitors in Breast and Ovarian Cancer},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {8},
  pages = {2357},
  doi = {10.3390/cancers15082357}
}
Kostenlos starten →